The Ratio of Serum Paraoxonase/Arylesterase Activity Using an Improved Assay for Arylesterase Activity to Discriminate PON1R192 from PON1Q192
Open Access
- 1 January 2003
- journal article
- research article
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 10 (6) , 337-342
Abstract
Human serum paraoxonase (PON1) exists in 2 major polymorphic forms: Q (glutamine) or R (arginine) at codon 192. The PON1192 activity polymorphism is substrate dependent. The PON1Q192 isoform has a higher rate of in vitro hydrolysis of diazoxon, sarin, and soman, whereas the PON1R192 isoform has higher activity for the hydrolysis of paraoxon and chlorpyrifos oxon. Both isoforms hydrolyze phenyl acetate at approximately the same rate. The present study described and evaluated a kinetic method of arylesterase activity determination with a modified fixed incubation method that used the oxidative coupling of phenol with 4-aminoantipyrine of phenyl acetate as the substrate. Our improved method shows that arylesterase activity is lower with the PON1R192 isoform than with the PON1Q192 isoform. The average activities of serum of individuals of a specific PON1Q192 genotype showed higher arylesterase and lower paraoxonase activity than the PON1R192 genotype. The ratio of paraoxonase/arylesterase activity showed a clear separation of all three PON1192 genotypes with no overlap between the groups (QQ: < 5.0, QR: 5.0−11.0, RR: > 11.0). PCR has suggested that the PON1192 phenotypes correspond to the PON1192 genotypes. Therefore, when conducting epidemiological or mechanistic studies that examine the role of PON1 in organophosphorus or lipid metabolism, this ratio is more useful and informative than a PCR-based genotype alone.Keywords
This publication has 28 references indexed in Scilit:
- Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1 192 or PON1 55 GenotypeArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Human Serum ParaoxonaseGeneral Pharmacology: The Vascular System, 1998
- Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.Journal of Clinical Investigation, 1997
- The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarinNature Genetics, 1996
- The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM StudyAtherosclerosis, 1996
- The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns.Journal of Clinical Investigation, 1996
- Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and LipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonaseAtherosclerosis, 1993
- The molecular basis of the human serum paraoxonase activity polymorphismNature Genetics, 1993
- MULTIPLE FORMS OF ESTERASE IN VERTEBRATE BLOOD PLASMA*Annals of the New York Academy of Sciences, 1961